Filter Results:
(3,179)
Show Results For
- All HBS Web
(3,179)
- People (7)
- News (429)
- Research (2,362)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,941)
Show Results For
- All HBS Web
(3,179)
- People (7)
- News (429)
- Research (2,362)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,941)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- November 1978 (Revised October 1989)
- Case
Amicon Corp. (B)
Details the negotiation between Amicon and three potential licensees, Jackson, Maynard-Smith and Behrstein. View Details
Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry
Capon, Noel. "Amicon Corp. (B)." Harvard Business School Case 579-094, November 1978. (Revised October 1989.)
- 08 Jun 2010
- First Look
First Look: June 8
empirical lacuna, we have developed a research program to measure the internal organization of firms—including their decentralization decisions—across a large range of industries and countries. Enamored with Scale: Scaling with Limited... View Details
Keywords: Martha Lagace
- 23 Feb 2009
- Research & Ideas
Creative Entrepreneurship in a Downturn
formation, and innovation. He is also a partner of the international management consulting firm McKinsey & Company, where he is a leader of its Innovation practice. Chakravorti has advised over 30 Fortune 500 companies on innovation, growth, and new... View Details
Keywords: by Martha Lagace
- 01 Jun 2017
- News
The Exchange: Venture Forth
illustration by Peter Arkle When Professor Paul Gompers began studying the venture capital industry in the late 1980s, colleagues often wondered why. “They’d say that it’s such a backwater and unimportant industry,” he recalls. With more... View Details
Keywords: April White
- 01 Jun 2015
- News
Ask the Expert: The Kids Are All Right
has not yet been chosen—industries where all the brands are perceived as the same. (Here, think financial services, health care, and retail.) These industries are most at risk for disruption by this... View Details
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
- December 2021 (Revised June 2022)
- Case
Darden Restaurants: The Nine Square Feet
By: Joshua D. Margolis and James Barnett
In June 2021, Darden Restaurants CEO Gene Lee contemplates how to position the world’s biggest full-service restaurant more than one year into the COVID-19 pandemic. View Details
Keywords: COVID-19 Pandemic; Agribusiness; Change; Decision Making; Food; Human Resources; Leadership; Operations; Strategy; Health Pandemics; Opportunities; Food and Beverage Industry; United States
Margolis, Joshua D., and James Barnett. "Darden Restaurants: The Nine Square Feet." Harvard Business School Case 422-004, December 2021. (Revised June 2022.)
- January 1990 (Revised March 1991)
- Case
American Red Cross Blood Services: Northeast Region
By: Robert L. Simons
Recounts the financial difficulties and management changes experienced by American Red Cross Blood Services: Northeast Region (NER) during the 1980s. After summarizing industry-wide changes in the collection, testing, and distribution of blood and blood products, the... View Details
Keywords: Change Management; Budgets and Budgeting; Financial Management; Restructuring; Health; SWOT Analysis; Social Enterprise; Marketplace Matching; Management Style; Organizational Culture; Organizational Change and Adaptation; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; North and Central America
Simons, Robert L. "American Red Cross Blood Services: Northeast Region." Harvard Business School Case 190-078, January 1990. (Revised March 1991.)
- 26 Apr 2011
- News
BioMine Strikes Gold
Contest. BioMine uses existing scaled-up mining industry technologies to capture value from the 40 million tons of "e-waste" that is landfilled or incinerated annually around the world. (Watch Bradoo explain the concept behind BioMine.)... View Details
- 01 Jun 2020
- News
Meal Plan
at a white-tablecloth restaurant. This year is looking a little different. On May 8, as some states loosened dining-in restrictions and others maintained strict guidelines for takeout and delivery only, the Bulletin held a virtual roundtable on the future of the View Details
- 13 May 2014
- First Look
First Look: May 13
how management and corporate boards of directors can best manage investor relations with activist stockholders such as hedge funds who are demanding major changes within a corporation to improve stockholder return. Beverage industry firm... View Details
Keywords: Sean Silverthorne
- Profile
Darrin Rahn
new markets, transparency, health and wellness, climate sustainability, and big macro responsibilities. HBS would allow me to reflect on the industry’s biggest future opportunities." "The HBS case method constantly inspires me... View Details
Keywords: CPG
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- 27 Apr 2021
- Research & Ideas
New Research: Surviving Bankruptcy, Useful Economics, and Retirement
use of remote patient monitoring services grows—driven by health care limitations imposed by the COVID-19 pandemic—clinicians, payers, and patients face important questions regarding the volume, value, and appropriate use of this care... View Details
- 08 Nov 2024
- Op-Ed
How Private Investors Can Help Solve Africa's Climate Crisis
as insurance against a starter who may get injured. Co-benefits are tangible and financeable. Health improvement and time savings, for example, are real benefits. We rode the new bus rapid transit (BRT) system in Dakar, Senegal. Local... View Details
- 01 Jan 2003
- News
Greylock
extraordinarily demanding group of fellow students and faculty. Developing the skills to listen carefully, think analytically, and communicate clearly is a requirement of leadership." CHARLES WAITE University of Connecticut, 1957 B.S., View Details
- Web
Field Course: Venture Capital Journey - Course Catalog
and startup company financing. In so doing, we aspire to prepare students for a career in venture capital, with a particular focus on their personal and professional growth and fulfillment. Further, we will provide a “systems thinking” lens to the View Details
- 06 Feb 2018
- First Look
First Look at New Research and Ideas: February 6, 2018
2018 Columbia Studies in the History of U.S. Capitalism American Capitalism: New Histories By: Beckert, Sven, and Christine Desan, eds. Abstract—The United States has long epitomized capitalism. From its enterprising shopkeepers, wildcat banks, violent slave... View Details
- November 18 2004
- Article
Merck's Recall of Rofecoxib: A Strategic Perspective
By: Felix Oberholzer-Gee and Noorein Inamdar
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.